news
AbbVie presents first study assessing the role of predefined doses of methotrexate when used in combination with HUMIRA® (adalimumab) for RA
Results from the CONCERTO trial...
12 June 2013 | By AbbVie
Results from the CONCERTO trial...
List view / Grid view
John R. Medich
news
AbbVie’s HUMIRA approved in the European Union
AbbVie announced that the European Commission has approved an extension…
2 April 2013 | By AbbVie
AbbVie announced that the European Commission has approved an extension of the EC marketing authorization for HUMIRA...
news
European Commission approves HUMIRA’s label update
AbbVie has announced the European Commission (EC) has approved an…
AbbVie has announced the European Commission (EC) has approved an update to the label for HUMIRA® (adalimumab) for the treatment of adults with moderate to severe rheumatoid arthritis (RA). The update adds data demonstrating the long-term clinical benefit of HUMIRA, making it the first and only biologic medication available with…
news
Abbott announces results of analysis exploring the use of HUMIRA® in simultaneously achieving three key treatment goals for RA
Results from a post-hoc analysis...
12 November 2012 | By Abbott
Results from a post-hoc analysis...
news
Abbott announces first long-term patient-reported health outcomes data for investigational use of HUMIRA® in patients with active nr-axSpA
The first long-term patient-reported health outcomes data...
12 November 2012 | By Abbott
The first long-term patient-reported health outcomes data...
